- Home
- MRP vs MRUS Comparison
MRP vs MRUS Comparison
Compare MRP & MRUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRP
- MRUS
- Stock Information
- Founded
- MRP N/A
- MRUS 2003
- Country
- MRP United States
- MRUS Netherlands
- Employees
- MRP N/A
- MRUS N/A
- Industry
- MRP
- MRUS Biotechnology: Pharmaceutical Preparations
- Sector
- MRP
- MRUS Health Care
- Exchange
- MRP NYSE
- MRUS Nasdaq
- Market Cap
- MRP 4.7B
- MRUS 4.1B
- IPO Year
- MRP N/A
- MRUS 2016
- Fundamental
- Price
- MRP $29.94
- MRUS $54.74
- Analyst Decision
- MRP Strong Buy
- MRUS Strong Buy
- Analyst Count
- MRP 2
- MRUS 13
- Target Price
- MRP $30.75
- MRUS $88.54
- AVG Volume (30 Days)
- MRP 1.2M
- MRUS 706.3K
- Earning Date
- MRP 07-31-2025
- MRUS 07-31-2025
- Dividend Yield
- MRP 8.70%
- MRUS N/A
- EPS Growth
- MRP N/A
- MRUS N/A
- EPS
- MRP N/A
- MRUS N/A
- Revenue
- MRP $82,698,000.00
- MRUS $54,732,000.00
- Revenue This Year
- MRP N/A
- MRUS $68.08
- Revenue Next Year
- MRP N/A
- MRUS $0.09
- P/E Ratio
- MRP N/A
- MRUS N/A
- Revenue Growth
- MRP N/A
- MRUS 42.77
- 52 Week Low
- MRP $21.02
- MRUS $33.19
- 52 Week High
- MRP $30.00
- MRUS $62.98
- Technical
- Relative Strength Index (RSI)
- MRP N/A
- MRUS 56.79
- Support Level
- MRP N/A
- MRUS $51.78
- Resistance Level
- MRP N/A
- MRUS $55.30
- Average True Range (ATR)
- MRP 0.00
- MRUS 1.63
- MACD
- MRP 0.00
- MRUS -0.11
- Stochastic Oscillator
- MRP 0.00
- MRUS 84.09
About MRP MILLROSE PROPERTIES INC.
Millrose Properties Inc is a Holding Company. The company along with its subsidiaries engages in providing operational and capital solutions for home builders and land development companies to finance the acquisition and development of land assets through its Homesite Option Purchase Platform.
About MRUS Merus N.V.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.